Summary
AbbVie Inc. (ABBV) has filed an 8-K report on April 3, 2024, to provide an update on its financial outlook for the first quarter and full year of 2024. The primary focus of this filing is the impact of acquired In-Process Research & Development (IPR&D) and milestones expenses. AbbVie anticipates these expenses will negatively impact both GAAP and non-GAAP diluted earnings per share by $0.08 in the first quarter.
Key Highlights
- 1AbbVie expects acquired IPR&D and milestones expenses of $164 million (pre-tax) for Q1 2024.
- 2These expenses are projected to reduce Q1 2024 GAAP and adjusted diluted EPS by $0.08.
- 3Full-year 2024 adjusted diluted EPS guidance is now $10.97 - $11.17, which includes the Q1 IPR&D/milestones impact.
- 4Q1 2024 adjusted diluted EPS guidance, including these expenses, is revised to $2.18 - $2.22.
- 5The company does not forecast acquired IPR&D and milestones expenses due to inherent uncertainty.
- 6Exhibit 99.1 provides detailed guidance including the impact of these specific expenses.
Frequently Asked Questions
These expenses relate to costs incurred from acquiring rights to research and development projects (IPR&D) or from achieving specific development milestones in collaborations or licensing agreements. They are often unpredictable in their timing and occurrence.
For the first quarter of 2024, AbbVie expects these expenses to reduce both GAAP and adjusted diluted earnings per share by $0.08. While this is a specific impact for Q1, the company generally does not forecast these types of expenses due to their unpredictable nature.
Yes, AbbVie has reaffirmed its full-year 2024 adjusted diluted earnings per share guidance range of $10.97 - $11.17, but this range now incorporates the impact of the first quarter's acquired IPR&D and milestones expenses.
AbbVie's updated adjusted diluted earnings per share guidance for the first quarter of 2024, including the impact of acquired IPR&D and milestones expenses, is now in the range of $2.18 to $2.22.